Remote functionalization of SCH 39166: Discovery of potent and selective benzazepine dopamine D1 receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 3, 2010, Pages 832-835

  Sasikumar, T K ^a   Burnett, Duane A ^a   Greenlee, William J ^a   Smith, Michelle ^a   Fawzi, Ahmad ^a   Zhang, Hongtao ^a   Lachowicz, Jean E ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Benzazepine; Dopamine antagonist; Ecopipam; Obesity; SCH 39166

Indexed keywords

BENZAZEPINE DERIVATIVE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; ECOPIPAM; DOPAMINE 1 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; PROTEIN BINDING;

AREA UNDER THE CURVE; ARTICLE; DRUG BINDING; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECTS; MALE; PHYSIOLOGY; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; BENZAZEPINES; DOPAMINE ANTAGONISTS; MALE; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1;

EID: 74049099560     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.12.094     Document Type: Article

References (25)

1. Kebabian J., and Calne D.B. Nature 277 (1979) 93
2. Claudi F., Stefano A.D., Napolitani F., Cingolani G.M., Giorgioni G., Fontenla J.A., Montenegro G.Y., Rivas M.E., Rosa E., Michelotto B., Orlando G., and Brunetti L. J. Med. Chem. 43 (2000) 599
3. Coffin, V. L. WO Patent 19990301, 1999.
4. Gold, E. H.; Chang, W. K. U.S. Patent 4284555, 1981.
5. Iorio L.C., Barnett A., Leitz F.H., Houser V.P., and Korduba C.A. Pharmacology 226 (1983) 462
6. Berger J.G., Chang W.K., Clader J.W., Hou D., Chipkin R.E., and Mcphail A.T. J. Med. Chem. 32 (1989) 1913
7. Andersen P.H., Gronvald F.C., Hohlweg R., Hansen L.B., Guddal E., Braestrup C., and Nielsen E.B. Eur. J. Pharmacol. 219 (1992) 45
8. Riddall D.R. Eur. J. Pharmacol. 210 (1992) 279
9. Kozlik, A.; Sargent, B. J.; Needham, P. L. WO Patent 9313073, 1993.
10. Witt T., Hock F.J., and Lehmann J. J. Med. Chem. 43 (2000) 2079
11. McQuade R.D., Duffy R.A., Coffin V.L., Chipkin R.E., and Barnett A. J. Pharmacol. Exp. Ther. 257 (1991) 42
12. Coffin, V.; Glue, P. W. WO Patent 9921540, 1999.
13. Astrup A., Greenway F.L., Ling W., Pedicone L., Lachowicz J., Strader C.D., and Kwan R. Obesity 15 (2007) 1717
14. Wu W.-L., Burnett D.A., Spring R., Greenlee W.J., Smith M., Favreau L., Fawzi A., Zhang H., and Lachowicz J.E. J. Med. Chem. 48 (2005) 680
15. Gala D., Dahanukar V.H., Eckert J.M., Lucas B.S., Schumacher D.P., Zavialov I.A., Buholzer P., Kubisch P., Mergelsberg I., and Scherer D. Org. Process Res. Dev. 8 (2004) 754
16. Ranu B.C., Sarkar D.C., and Chakraborty R. Synth. Commun. 22 (1992) 1095
17. +.
18. Compound 5b was prepared according to the following reference. Maligres P.E., Waters M.S., Fleitz F., and Askin D. Tetrahedron Lett. (1999) 8193
19. Compound 5c and 5d were prepared according to the following reference. Banwell M.G., Bonadio A., Turner K.A., Ireland N.K., and Mackay M.F. Aust. J. Chem. 46 (1993) 325
20. Compound 5e was prepared according to the following references:. Weller D.D., and Stirchak E.P. J. Org. Chem. 48 (1983) 4873
21. Ellis J.E., and Lenger S.R. Synth. Commun. (1998) 1517
22. Compound 5f was prepared according to the following reference. Aebischer E., Bacher E., Demnitz F.W.J., Keller T.H., Kurzmeyer M., Ortiz M.L., Pombo-Villar E., and Weber H.-P. Heterocycles 48 (1998) 2225
23. Miyaura N., Yanagi T., and Suzuki A. Synth. Commun. (1981) 513
24. i values from four separate determinations are reported. The SEM was below 15% in each case.
25. Korfmacher W.A., Cox K.A., Ng K.J., Veals J., Hsieh Y., Wainhaus S., Broske L., Prelusky D., Nomeir A., and White R.E. Rapid Commun. Mass Spectrom. 15 (2001) 335 Data are from pooled samples from two mice in cassette-accelerated rapid rat protocol as described in the above reference. Briefly, two male Sprauge-Dawley rats were dosed orally at a dose of 10 mg/kg. Blood samples were collected at different time points and analyzed according to Ref. 21. Compound plasma levels for individual animals used to calculate PK parameters were generally with ±25% of average values